The US Oncology Network | Association Partnerships

In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed real-world findings from a trial evaluating second-line maintenance niraparib in patients with recurrent ovarian cancer.

Niraparib as a monotherapy is supported as standard of care for a broad patient population with advanced ovarian cancer after first-line platinum-based chemotherapy.

The US Oncology Network announced today that Cancer Center of Kansas has joined them, effective July 1, 2023, by entering into a new managed services partnership.

Second-line maintenance therapy with niraparib improved overall survival in a BRCA gene wild-type population with recurrent ovarian cancer.

Real-world evidence support the use of venetoclax-based regimens for patients with chronic lymphocytic leukemia based the consistent efficacy shown between the real-world and clinical trial data.

In the past 7 years, treatment for patients with non–small cell lung cancer has increased by over 100%, according to real-world data presented at iSPOR 2023.

Ontada announces seven research presentations at ISPOR 2023, including a new framework for assessing the quality of real-world data, which has been selected as a top 5% finalist for the ISPOR Research Presentation Awards.

Becoming a member of The Network enables growth opportunities for community practices, promoting high-quality, independent oncology care.

Nicholas J. Robert, MD, discusses the poster on the MYLUNG Consortium that he presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Medically integrated dispensing pharmacies in oncology often deal with complex PAs that can inhibit delivery of timely, quality care and consume staff resources.

Nicholas J. Robert, MD, discusses the main findings from the MYLUNG Consortium.

Following positive data from the phase 1 ReSPECT-GBM trial, the first patient has been dosed with rhenium (186Re) obisbemeda in the phase 2 portion.

For cervical cancer awareness month, Lauren Bollinger, MD, discusses how the increase in research in the field of cervical cancer is driving the progress of treatment.

Bradley Monk, MD, FACCOG, FACS, discusses main takeaways from the OUTBACK trial of adjuvant chemotherapy following chemoradiation as primary treatment in patients with locally advanced cervical cancer vs chemoradiation alone.

Kruti Patel, DO, reviews the advancements, landmark trials, and challenges with CAR T-cell therapy for Cancer Immunotherapy Month.

During an interview with Targeted Oncology, Nicholas J. Robert, MD, further discussed the data of the MYLUNG study which he presented in a poster at the 2022 American Society of Clinical Oncology Annual Meeting.

Patients with platinum-sensitive ovarian cancer treated with maintenance rucaparib in the ATHENA-MONO trial showed a significant improvement in progression-free survival when compared with placebo in the first-line setting, regardless of HRD status.

Given the rapid pace of advancements in the diagnosis and treatment of prostate cancer, the greatest challenge may be coordinating these advances and applying them to disease management.

Bradley Monk, MD, FACCOG, FACS, discusses the creation and findings of the OUTBACK trial.

With custom QCDR measures identified by physician leaders in The US Oncology Network, McKesson has been received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System as a registry.

Bradley J. Monk, MD, FACOG, FACS, discusses the use of immune checkpoint inhibitors to treat cervical cancer.

According to Bradley J. Monk, MD, FACOG, FACS, cemiplimab achieved better response and a longer overall survival compared with chemotherapy in patients with cervical cancer.

Fourteen practices from the US Oncology Network Participate in the Oncology Care Model.

From precision radiotherapeutics to small molecule inhibitors, Scott Paulson, MD, discusses a new array of pharmacological treatments for World Neuroendocrine Cancer Day.

New findings from the phase 3 monarchE recently led to an FDA approval for abemaciclib. Joyce O’Shaughnessy, MD, presented the long-term analysis results during an ESMO Virtual Plenary.

Moshe Levy, MD discusses the ongoing phase 3b study of asciminib in patients with chronic myeloid leukemia in chronic phase.

In the MagnetisMM-1 study, elranatamab induces response with tolerable safety in patients with relapsed or refractory multiple myeloma.

During a Targeted Oncology Case-Based Roundtable event, John M. Burke, MD, discussed the challenges with treating relapsed or refractory diffuse large B-cell lymphoma with a group of peers.

In an interview with Dana Chase, MD during the ESMO Congress 2021, Chase discussed unmet needs for frontline advanced ovarian cancer treatment and the retrospective analysis of cumulative risk factors and their potential impact on outcome in these patients.

In season 2, episode 8 of Targeted Talks, Thomas Hutson, DO, PharmD, and Rana R. McKay, MD, discuss the renal cell carcinoma paradigm and challenges to overcome in the future.